Platelet-activating factor-induced NF-κB activation enhances VEGF expression through a decrease in p53 activity

FEBS Letters

Volumn 580, Issue 13, 2006, Pages 3006-3012

  Ko, Hyun Mi ^a,b   Jung, Hae Hyun ^a   Seo, Kook Heon ^a   Kang, Yeong Rim ^a   Kim, Han A ^a   Park, Sung Jun ^a   Lee, Hern Ku ^b   Im, Suhn Young ^a  

^a Chonnam National University   (South Korea)

^b Chonbuk National University Medical School   (South Korea)

Author keywords

NF B; p53; PAF; VEGF

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; THROMBOCYTE ACTIVATING FACTOR; VASCULOTROPIN;

ARTICLE; CANCER CELL; CELL CULTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS;

CELLS, CULTURED; DOWN-REGULATION; HUMANS; PLATELET ACTIVATING FACTOR; PROMOTER REGIONS (GENETICS); TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33646587342     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2006.04.042     Document Type: Article

References (39)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat. Med. 1 (1995) 27-31
2. Fidler I.J., and Ellis L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79 (1994) 185-188
3. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., and Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 (1989) 1306-1309
4. Plate K.H., Breier G., Weich H.A., and Risau W. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 359 (1992) 845-848
5. Millauer B., Shawver L.K., Plate K.H., Risau W., and Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367 (1994) 576-579
6. Tischer E., Mitchell R., Hartman T., Silva M., Gospodarowicz D., Fiddes J.C., and Abraham J.A. The human gene for vascular endothelial growth factor. J. Biol. Chem. 266 (1991) 11947-11954
7. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., and Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16 (1996) 4604-4613
8. Ryuto M., Ono M., Izumi H., Yoshida S., Weich H.A., Kohno K., and Kuwano M. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J. Biol. Chem. 271 (1996) 28220-28228
9. Damert A., Ikeda E., and Risau W. Activating-protein-1 binding potentiates the hypoxia-induciblefactor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. Biochem. J. 327 (1997) 419-423
10. Oyama T., Sakuta T., Matsushita K., Maruyama I., Nagaoka S., and Torii M. Effects of roxithromycin on tumor necrosis factor-alpha-induced vascular endothelial growth factor expression in human periodontal ligament cells in culture. J. Periodontol. 71 (2000) 1546-1553
11. Fukuda A.I., and Breuel K.F. Effect of platelet activating factor on embryonic development and implantation in the mouse. Hum. Reprod. 11 (1996) 2746-2749
12. Nilsson G., Metclfe D.D., and Taub D.D. Demonstration that platelet-activating factor is capable of activating mast cells and inducing a chemotactic response. Immunology 99 (2000) 314-319
13. Toledano B.J., Bastien Y., Noya F., and Mazer B. Characterization of B lymphocytes rescued from apoptosis by platelet-activating factor. Cell Immunol. 191 (1999) 60-68
14. Braquet P., Paubert-Braquet M., Bourgain R.H., Bussolino F., and Hosford D. PAF/cytokine auto-generated feedback networks in microvascular immune injury: consequences in shock, ischemia and graft rejection. J. Lipid Mediat. 1 (1989) 75-112
15. Ghosh S. Regulation of inducible gene expression by the transcription factor NF-kappaB. Immunol. Res. 19 (1999) 183-189
16. Kopp E.B., and Ghosh S. NF-kappa B and rel proteins in innate immunity. Adv. Immunol. 58 (1995) 1-27
17. Im S.Y., Han S.J., Ko H.M., Choi J.H., Chun S.B., Lee D.G., Ha T.Y., and Lee H.K. Involvement of nuclear factor-κB in platelet-activating factor-mediated tumor necrosis factor-alpha expression. Eur. J. Immunol. 27 (1997) 2800-2804
18. Han S.J., Choi J.H., Ko H.M., Choi I.W., Lee H.K., Lee O.H., and Im S.Y. Glucocorticoids prevent NF-κB activation by inhibiting the early release of platelet-activating factor in response to lipopolysaccharide. Eur. J. Immunol. 29 (1999) 1334-1341
19. Choi J.H., Ko H.M., Kim J.W., Lee H.K., Han S.S., Chun S.B., and Im S.Y. Platelet-activating factor-induced early activation of NF-κB plays a crucial role for organ clearance of Candida albicans. J. Immunol. 166 (2001) 5139-5144
20. Ko H.M., Seo K.H., Han S.J., Ahn K.Y., Choi I.H., Koh G.Y., Lee H.K., Ra M.S., and Im S.Y. NF-κB-dependency of platelet-activating factor-induced angiogenesis. Cancer Res. 62 (2002) 1809-1814
21. Abeyama K., Eng W., Jester J.V., Vink A.A., Edelbaum D., Cockerell C.J., Bergstresser P.R., and Takashima A. A role for NF-kappaB-dependent gene transactivation in sunburn. J. Clin. Invest. 105 (2000) 1751-1759
22. Shibata A., Nagaya T., Imai T., Funahashi H., Nakao A., and Seo H. Inhibition of NF-kappaB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Res. Treat. 73 (2002) 237-243
23. Linderholm B., Lindh B., Tavelin B., Grankvist K., and Henriksson R. p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int. J. Cancer 89 (2000) 51-62
24. Mukhopadhyay D., Tsiokas L., and Sukhatme V.P. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 55 (1995) 6161-6165
25. Rak J., Mitsuhashi Y., Bayko L., Filmus J., Shirasawa S., Sasazuki T., and Kerbel R.S. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 55 (1995) 4575-4580
26. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q., Dillehay L.E., Madan A., Semenza G.L., and Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14 (2000) 34-44
27. Nagayama Y., Shigematsu K., Namba H., Zeki K., Yamashita S., and Niwa M. Inhibition of angiogenesis and tumorigenesis, and induction of dormancy by p53 in a p53-null thyroid carcinoma cell line in vivo. Anticancer Res. 20 (2000) 2723-2728
28. Hellin A.C., Calmant P., Gielen J., Bours V., and Merville M.P. Nuclear factor-kappaB-dependent regulation of p53 gene expression induced by daunomycin genotoxic drug. Oncogene 16 (1998) 1187-1195
29. Wu H., and Lozano G. NF-kappa B activation of p53. A potential mechanism for suppressing cell growth in response to stress. J. Biol. Chem. 269 (1994) 20067-20074
30. Ravi R., Mookerjee B., van Hensbergen Y., Bedi G.C., Giordano A., El-Deiry W.S., Fuchs E.J., and Bedi A. p53-mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300. Cancer Res. 58 (1998) 4531-4536
31. Wadgaonkar R., Phelps K.M., Haque Z., Williams A.J., Silverman E.S., and Collins T. CREB-binding protein is a nuclear integrator of nuclear factor-kappaB and p53 signaling. J. Biol. Chem. 274 (1999) 1879-1882
32. Bartke T., Siegmund D., Peters N., Reichwein M., Henkler F., Scheurich P., and Wajant H. p53 upregulates cFLIP, inhibits transcription of NF-kappaB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. Oncogene 20 (2001) 571-580
33. Pise-Masison C.A., Mahieux R., Jiang H., Ashcroft M., Radonovich M., Duvall J., Guillerm C., and Brady J.N. Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-kappaB pathway and is dependent on p53 phosphorylation. Mol. Cell. Biol. 20 (2000) 3377-3386
34. Takahashi K., Sawasaki Y., Hata J., Mukai K., and Goto T. Spontaneous transformation and immortalization of human endothelial cells. In Vitro Cell Dev. Biol. 26 (1990) 265-274
35. Ko H.M., Park Y.M., Jung B., Kim H.A., Choi J.H., Park S.J., Lee H.K., and Im S.Y. Involvement of matrix metalloproteinase-9 in platelet-activating factor-induced angiogenesis. FEBS Lett. 579 (2005) 2369-2375
36. Rodrigues N.R., Rowan A., Smith M.E.F., Kerr I.B., Bodmer W.F., Gannon J.V., and Lane D.P. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA 87 (1990) 7555-7559
37. Ikeda A., Sun X., Li Y., Zhang Y., Eckner R., Doi T.S., Takahashi T., Obata Y., Yoshioka K., and Yamamoto K. p300/CBP-dependent and -independent transcriptional interference between NF-kappaB RelA and p53. Biochem. Biophys. Res. Commun. 272 (2000) 375-379
38. Pal S., Datta K., and Mukhopadhyay D. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res. 61 (2001) 6952-6957
39. Pollmann C., Huang X., Mall J., Bech-Otschir D., Naumann M., and Dubiel W. The constitutive photomorphogenesis 9 signalocome directs vascular endothelial growth factor production in tumor cells. Cancer Res. 61 (2001) 8416-8421